Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BIIB

Biogen Inc

May 27 • 04:00PM ET

196.97

+3.89 2.01 %

Healthcare • Drug Manufacturers - General • USA • Large • NASD

Peers: AMGN GILD REGN VRTX ALNY ARGX BMY LLY MRK PFE

| Held by: VTI VOO VO IVV SPY VTV IBB XLV VOE RSP

Index	S&P 500	P/E	21.14	EPS (ttm)	9.32	Insider Own	0.89%	Shs Outstand	147.60M	Perf Week	3.36%
Market Cap	29.08B	Forward P/E	12.07	EPS next Y	16.31	Insider Trans	-0.26%	Shs Float	146.32M	Perf Month	9.02%
Enterprise Value	31.36B	PEG	2.06	EPS next Q	3.18	Inst Own	93.77%	Short Float	3.06%	Perf Quarter	3.27%
Income	1.37B	P/S	3.03	EPS this Y	-4.33%	Inst Trans	-1.48%	Short Ratio	3.86	Perf Half Y	12.36%
Sales	9.60B	P/B	1.56	EPS next Y	11.60%	ROA	4.77%	Short Interest	4.48M	Perf YTD	11.92%
Book/sh	126.37	P/C	6.79	EPS next 5Y	5.85%	ROE	7.70%	52W High	205.97 -4.37%	Perf Year	53.42%
Cash/sh	29.01	P/FCF	12.00	EPS past 3/5Y	-25.04% -18.74%	ROIC	5.44%	52W Low	121.05 62.72%	Perf 3Y	-34.05%
Dividend Est.	-	EV/EBITDA	10.14	Sales past 3/5Y	0.35% -5.06%	Gross Margin	66.29%	Volatility	2.65% 3.06%	Perf 5Y	-26.33%
Dividend TTM	-	EV/Sales	3.27	EPS Y/Y TTM	-7.88%	Oper. Margin	23.87%	ATR (14)	5.75	Perf 10Y	-24.38%
Dividend Ex-Date	-	Quick Ratio	2.41	Sales Y/Y TTM	2.11%	Profit Margin	14.29%	RSI (14)	57.80	Recom	2.05
Dividend Gr. 3/5Y	- -	Current Ratio	3.06	EPS Q/Q	31.24%	SMA20	2.26%	Beta	0.20	Target Price	219.86
Payout	0.00%	Debt/Eq	0.35	Sales Q/Q	2.88%	SMA50	5.77%	Rel Volume	0.77	Prev Close	193.08
Employees	7500	LT Debt/Eq	0.35	Earnings	Apr 29 BMO	SMA200	15.95%	Avg Volume	1.16M	Price	196.97
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.91% 8.35%	Trades		Volume	893,029	Change	2.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Resumed	Evercore ISI	Outperform
Apr-22-26	Upgrade	UBS	Neutral → Buy	$225
Apr-20-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$250
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$214
Feb-20-26	Initiated	Barclays	Equal Weight	$185
Feb-09-26	Reiterated	H.C. Wainwright	Buy	$194 → $228
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold

Show Previous Ratings

May-22-26 06:46AM	Parkinsons drug from Biogen, Denali comes up short (BioPharma Dive)
May-21-26 07:03PM	BIIB, DNLI Stocks Edge Lower After Hours: Parkinsons Drug Misses Key Goals In Trial (Stocktwits)
06:00PM	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease (GlobeNewswire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-15-26 09:45AM	Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Loading…
07:44AM	Biogen completes $5.3B Apellis Pharmaceuticals acquisition (Quartz)
May-14-26 07:19PM	Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug (GuruFocus.com) -6.43%
04:30PM	Biogen Inc. stock underperforms Thursday when compared to competitors (MarketWatch)
01:03PM	Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery. (Investor's Business Daily)
10:08AM	Biogen Shares Surge After Positive Mid-Stage Alzheimers Trial Results (InvestorsHub)
10:07AM	Biogen Stock Falls on Alzheimer's Drug Trial Miss (The Wall Street Journal)
09:07AM	Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway. (Barrons.com)
08:35AM	Biogen Completes Acquisition of Apellis Pharmaceuticals (GlobeNewswire)
07:40AM	Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimers (Investing.com)
06:59AM	Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:07AM	Loading…
May-08-26 06:07AM	FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended (BioPharma Dive)
02:30AM	Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease (GlobeNewswire)
May-07-26 06:01PM	Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 (PR Newswire)
04:01PM	Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
May-01-26 06:51AM	Bristol Myers legacy lift, Biogens blue skies and Regenerons murky outlook (BioPharma Dive)
Apr-30-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates (Business Wire)
03:06AM	Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Apr-29-26 12:48PM	Biogen Inc. Q1 2026 Earnings Call Summary (Moby) +6.00%
07:25AM	Biogen Updates 2026 Guidance (RTT News)
07:02AM	Biogen Lowers 2026 Earnings Outlook (The Wall Street Journal)
06:42AM	Biogen shares rise after Q1 beat; full-year profit outlook slashed (Investing.com)
06:04AM	Biogen Walloped Wall Street's First Quarter Views; Here's What Happened (Investor's Business Daily)
Apr-27-26 05:22AM	Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. (Barrons.com)
Apr-24-26 11:54AM	Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal (Pharmaceutical Technology)
Apr-22-26 01:15PM	Biogen upgraded by UBS on slew of pipeline catalysts going into 2027 (Proactive)
10:20AM	Loading…
10:20AM	UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts (Investing.com)
09:35AM	Airbnb upgraded, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Apr-20-26 09:33AM	Qorvo downgraded, Ulta Beauty upgraded: Wall Street's top analyst calls (The Fly)
07:30AM	Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region (GlobeNewswire)
Apr-18-26 09:00AM	These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. (MarketWatch)
Apr-16-26 07:00AM	Replimune cuts staff; MeiraGTx reacquires eye gene therapy (BioPharma Dive)
Apr-14-26 09:53AM	Tesla upgraded, AppLovin initiated: Wall Street's top analyst calls (The Fly)
Apr-08-26 04:01PM	Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
05:37AM	Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs expected study failure (BioPharma Dive)
Apr-07-26 04:01PM	Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors (Business Wire)
12:01AM	Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal (The Daily Upside)
Apr-03-26 06:10PM	Where the New Houses Are-and What That Says About Growth (Barrons.com)
Apr-01-26 01:15PM	Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets (BioPharma Dive)
09:46AM	Disney upgraded, Nike downgraded: Wall Street's top analyst calls (The Fly)
07:36AM	Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout (Pharmaceutical Technology)
Mar-31-26 08:00PM	The Year Is Off to the Strongest Start for Big Deals Ever (The Wall Street Journal)
05:46PM	Big Drug Companies Hunting for Deals Are Lowering Their Sights (The Wall Street Journal)
05:11PM	Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement (GuruFocus.com)
02:43PM	Nasdaq shoots higher, Dow adds momentum as Trump looks for end to war (Proactive)
12:20PM	Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio (Proactive)
11:27AM	Nvidia invests $2B in Marvell, Eli Lilly to buy drugmaker Centessa (Yahoo Finance Video)
09:47AM	Stocks to Watch Tuesday: McCormick, Unilever, Marvell, Centessa, Apellis (The Wall Street Journal)
09:41AM	Why This Pharma Stock More Than Doubled Today (Barrons.com)
09:07AM	Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars (Investor's Business Daily)
08:07AM	Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases (MarketWatch)
07:44AM	Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion (The Wall Street Journal)
06:59AM	Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology (GlobeNewswire)
Mar-30-26 04:01PM	Treasuries Climb as Powell Eases Fed-Hike Jitters: Markets Wrap (Bloomberg)
12:11PM	Biogen high-dose Spinraza approval seen supporting long-term growth (Proactive)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
07:30AM	FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire)
Mar-28-26 03:00PM	Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity (GlobeNewswire)
Mar-20-26 12:05PM	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 (GlobeNewswire)
Mar-19-26 07:30AM	Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-11-26 01:51PM	Biogen Stock: Is BIIB Outperforming the Healthcare Sector? (Barchart)
08:00AM	Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy (GlobeNewswire)
Mar-09-26 11:35PM	Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks (StockStory)
Mar-06-26 04:18PM	Biogen CEO touts new era of growth at TD Cowen as 10 Phase 3 programs near key readouts (MarketBeat)
10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
07:39AM	Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? (Zacks)
Mar-05-26 08:36AM	What Makes Biogen (BIIB) an Attractive Long-Term Holding? (Insider Monkey)
07:30AM	Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences (GlobeNewswire)
Mar-04-26 05:06PM	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Feb-27-26 09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
Feb-26-26 10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
07:35AM	Is Vertex Stock Outperforming the Dow? (Barchart)
Feb-24-26 04:01PM	Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-23-26 12:59PM	This Rare Disease Biotech Name Teases Around A Buy Point (Investor's Business Daily)
09:50AM	Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock (Zacks)
Feb-20-26 03:49PM	Top Analyst Reports for Philip Morris, Lockheed Martin & Danaher (Zacks)
Feb-19-26 09:40AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
Feb-18-26 05:22AM	An Alzheimers startup emerges with $175M in venture backing (BioPharma Dive)
Feb-16-26 06:17AM	What Are Wall Street Analysts' Target Price for Biogen Stock? (Barchart)
Feb-13-26 11:22AM	Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus (MarketBeat)
10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
09:57AM	Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 - Here's Why (Insider Monkey)
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
12:36AM	The 5 Most Interesting Analyst Questions From Biogen's Q4 Earnings Call (StockStory)
Feb-12-26 11:41PM	1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky (StockStory)
Feb-11-26 05:00PM	Biogen Announces Board Chair Transition (GlobeNewswire)
04:47AM	Analyst Report: Biogen Inc. (Morningstar Research)
Feb-08-26 09:00PM	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China (GlobeNewswire)
05:31PM	Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump (Benzinga)
Feb-07-26 12:31AM	BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds (StockStory)
Feb-06-26 07:43PM	Analyst Report: Biogen Inc. (Morningstar Research) +8.53%
04:02PM	Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... (GuruFocus.com)
03:48PM	Biogen stock pops, Robinhood gets lift as bitcoin ticks up (Yahoo Finance Video)
11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

PresidentMr. Christopher A. Viehbacher

Executive VP & CFOMs. Robin C. Kramer

Executive VP and Head of Pharmaceutical Operations & TechnologyMs. Nicole Murphy

J.D.Ms. Susan H. Alexander Esq.

M.P.H.Dr. Priya Singhal M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	0.00	939	0	6,820	May 05 04:11 PM
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	0.00	181	0	1,396	Apr 03 04:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	195.03	3	585	19,611	Feb 17 08:16 PM
Viehbacher Christopher	President and CEO	Feb 06 '26	Option Exercise	0.00	24,461	0	36,548	Feb 10 05:06 PM
Singhal Priya	Head of Development	Feb 06 '26	Option Exercise	0.00	6,900	0	12,115	Feb 10 05:05 PM
Singhal Priya	Head of Development	Feb 09 '26	Sale	199.83	2,660	531,548	8,043	Feb 10 05:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 06 '26	Option Exercise	0.00	8,725	0	21,016	Feb 10 05:03 PM
Kramer Robin	Chief Financial Officer	Feb 06 '26	Option Exercise	0.00	5,003	0	12,535	Feb 10 05:02 PM
Keeney Adam	Head of Corporate Development	Feb 06 '26	Option Exercise	0.00	5,080	0	6,875	Feb 10 05:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 06 '26	Option Exercise	0.00	6,889	0	11,786	Feb 10 05:00 PM
Grogan Jane	Head of Research	Feb 06 '26	Option Exercise	0.00	3,258	0	4,642	Feb 10 04:59 PM
Gregory Ginger	EVP, Human Resources	Feb 06 '26	Option Exercise	0.00	7,183	0	23,491	Feb 10 04:58 PM
Godbout Sean	Chief Accounting Officer	Feb 06 '26	Option Exercise	0.00	1,079	0	1,395	Feb 10 04:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 06 '26	Option Exercise	0.00	9,046	0	43,321	Feb 10 04:55 PM
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	199.83	2,660	531,548		Feb 09 10:14 AM
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM

Open in Screener

VSTM

Verastem Inc

May 27 • 04:00PM ET

4.25

-0.11 -2.52 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: VTI XBI IWM VXF FESM VTWO IWO IWN IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.74	Insider Own	6.43%	Shs Outstand	87.84M	Perf Week	2.41%
Market Cap	373.46M	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-0.71%	Shs Float	82.22M	Perf Month	-23.29%
Enterprise Value	277.25M	PEG	-	EPS next Q	-0.43	Inst Own	88.17%	Short Float	21.31%	Perf Quarter	-27.10%
Income	-193.96M	P/S	7.53	EPS this Y	48.67%	Inst Trans	0.56%	Short Ratio	8.05	Perf Half Y	-57.50%
Sales	49.59M	P/B	4.57	EPS next Y	30.70%	ROA	-107.90%	Short Interest	17.52M	Perf YTD	-44.95%
Book/sh	0.93	P/C	2.06	EPS next 5Y	41.17%	ROE	-786.15%	52W High	11.24 -62.21%	Perf Year	-50.12%
Cash/sh	2.07	P/FCF	-	EPS past 3/5Y	12.90% 10.63%	ROIC	-120.50%	52W Low	4.00 6.25%	Perf 3Y	-64.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 10.80%	Gross Margin	82.91%	Volatility	6.42% 6.79%	Perf 5Y	-91.15%
Dividend TTM	-	EV/Sales	5.59	EPS Y/Y TTM	21.44%	Oper. Margin	-344.56%	ATR (14)	0.34	Perf 10Y	-76.23%
Dividend Ex-Date	-	Quick Ratio	3.00	Sales Y/Y TTM	395.85%	Profit Margin	-391.16%	RSI (14)	33.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.04	EPS Q/Q	61.29%	SMA20	-13.34%	Beta	0.29	Target Price	16.00
Payout	-	Debt/Eq	1.05	Sales Q/Q	-	SMA50	-20.66%	Rel Volume	1.28	Prev Close	4.36
Employees	102	LT Debt/Eq	0.97	Earnings	May 07 AMC	SMA200	-42.62%	Avg Volume	2.18M	Price	4.25
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.43% -12.87%	Trades		Volume	2,785,218	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	BTIG Research	Buy	$19
Feb-04-26	Initiated	H.C. Wainwright	Buy	$18
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14

Show Previous Ratings

Today 07:30AM	Verastem Oncology to Present at Jefferies Healthcare Conference (Business Wire)
May-26-26 07:30AM	Verastem Oncology Appoints Michael P. Bailey to its Board of Directors (Business Wire)
May-12-26 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire) -5.12%
May-08-26 07:30AM	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer (Business Wire) -13.60%
May-07-26 05:16PM	Verastem: Q1 Earnings Snapshot (Associated Press) -5.82%
04:01PM	Loading…
04:01PM	Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Apr-30-26 07:30AM	Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Apr-23-26 07:30AM	Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-10-26 07:00AM	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire) -5.01%
Apr-02-26 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-17-26 06:03PM	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
04:44PM	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
Mar-05-26 08:30AM	Verastem, Inc. Q4 2025 Earnings Call Summary (Moby) +5.85%
12:03AM	Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
Mar-04-26 08:48PM	Verastem Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Loading…
05:10PM	Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:20PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Feb-18-26 07:30AM	Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
Feb-17-26 12:00PM	What Makes Verastem (VSTM) a New Buy Stock (Zacks)
Feb-16-26 01:02AM	Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
07:57AM	Loading…
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

PresidentMr. Daniel W. Paterson

Chief Financial OfficerMr. Daniel Calkins

Ph.D.Dr. Michael Glen Kauffman M.D.

Co-Founder & Chair of Scientific Advisory BoardDr. Robert A. Weinberg Ph.D.

Ph.D.Dr. Michelle Detwiler M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gagnon Robert E.	Director	May 27 '26	Proposed Sale	4.36	20,103	87,649		May 27 04:47 PM
Paterson Dan	President and CEO	May 04 '26	Sale	5.82	806	4,691	612,113	May 06 04:01 PM
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM
Bunn Paul A.	Director	Oct 09 '25	Sale	9.06	8,333	75,497	8,333	Oct 14 04:31 PM
Bunn Paul A.	Board Member	Oct 09 '25	Proposed Sale	8.94	8,333	74,497		Oct 09 04:05 PM
Calkins Daniel	Chief Financial Officer	Sep 22 '25	Sale	9.08	57	518	109,863	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '25	Sale	9.23	25	231	109,838	Sep 24 04:30 PM
Stuglik Brian M	Director	Sep 16 '25	Sale	9.99	587	5,864	101,739	Sep 18 06:16 PM
Gagnon Robert E.	Director	Sep 16 '25	Sale	9.99	281	2,807	41,961	Sep 18 06:14 PM
Paterson Dan	President and CEO	Sep 16 '25	Sale	9.99	390	3,896	442,117	Sep 18 06:11 PM
Paterson Dan	Officer	Sep 17 '25	Proposed Sale	9.76	31,790	310,429		Sep 04 12:39 PM
Paterson Dan	President and CEO	Aug 06 '25	Sale	5.81	1,332	7,739	442,507	Aug 06 08:38 PM
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM
Paterson Dan	President and CEO	Jun 16 '25	Sale	5.65	335	1,893	461,647	Jun 20 11:22 AM
Gagnon Robert E.	Director	Jun 16 '25	Sale	5.65	284	1,605	42,242	Jun 20 11:22 AM
Stuglik Brian M	Director	Jun 16 '25	Sale	5.65	594	3,356	102,326	Jun 20 11:21 AM

Open in Screener

FBIO

Fortress Biotech Inc

May 27 • 04:00PM ET

2.76

+0.07 2.60 %

Healthcare • Biotechnology • USA • Micro • NASD

FBIO Fortress Biotech Inc daily Stock Chart

Peers: ANIX ATYR COYA CYPH EXOZ INO LONA NRXS NRXP KALA

| Held by: VTI VXF IWC

Index	-	P/E	0.87	EPS (ttm)	3.18	Insider Own	32.00%	Shs Outstand	33.19M	Perf Week	9.09%
Market Cap	91.69M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.00%	Shs Float	22.59M	Perf Month	21.59%
Enterprise Value	-70.35M	PEG	-	EPS next Q	-0.20	Inst Own	16.43%	Short Float	20.58%	Perf Quarter	-22.25%
Income	119.20M	P/S	1.39	EPS this Y	3528.57%	Inst Trans	-2.55%	Short Ratio	10.95	Perf Half Y	6.56%
Sales	66.16M	P/B	0.56	EPS next Y	-120.83%	ROA	47.77%	Short Interest	4.65M	Perf YTD	-24.59%
Book/sh	4.89	P/C	0.36	EPS next 5Y	-	ROE	138.54%	52W High	4.53 -39.07%	Perf Year	50.82%
Cash/sh	7.70	P/FCF	0.60	EPS past 3/5Y	83.35% 62.98%	ROIC	60.52%	52W Low	1.70 62.35%	Perf 3Y	-66.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.83% 6.77%	Gross Margin	59.13%	Volatility	4.81% 5.55%	Perf 5Y	-95.16%
Dividend TTM	-	EV/Sales	-1.06	EPS Y/Y TTM	266.92%	Oper. Margin	-84.36%	ATR (14)	0.14	Perf 10Y	-93.50%
Dividend Ex-Date	-	Quick Ratio	2.77	Sales Y/Y TTM	14.50%	Profit Margin	180.16%	RSI (14)	63.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	686.87%	SMA20	12.42%	Beta	1.20	Target Price	11.00
Payout	-	Debt/Eq	0.33	Sales Q/Q	22.06%	SMA50	9.20%	Rel Volume	0.60	Prev Close	2.69
Employees	78	LT Debt/Eq	0.30	Earnings	May 14 AMC	SMA200	-6.76%	Avg Volume	424.52K	Price	2.76
IPO	Nov 17, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	1381.82% -1.84%	Trades		Volume	254,535	Change	2.60%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

May-19-26 04:45PM	Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-18-26 08:30AM	Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference (GlobeNewswire)
May-14-26 04:50PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press)
04:10PM	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-26 04:01PM	Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Loading…
May-06-26 04:01PM	Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 (GlobeNewswire) -5.88%
May-04-26 08:30AM	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-21-26 08:30AM	Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi (GlobeNewswire)
Mar-31-26 05:46PM	Fortress Biotech: Q4 Earnings Snapshot (Associated Press) -11.47%
04:05PM	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-30-26 04:05PM	Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Mar-25-26 04:01PM	Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-18-26 08:30AM	Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 (GlobeNewswire)
Feb-24-26 08:53AM	Fortress Biotechs Cyprium enters agreement to sell PRV for $205M (TipRanks)
Feb-23-26 09:24AM	UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
08:30AM	Loading…
08:30AM	Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million (GlobeNewswire)
Feb-05-26 12:56PM	Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes (Zacks)
Jan-28-26 12:21PM	Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums (Zacks)
Jan-21-26 01:29PM	Centene Expands Palliative Care Access in Ohio Through Tuesday Health (Zacks)
Jan-14-26 06:06AM	Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease (Pharmaceutical Business Review) -15.90%
Jan-13-26 07:45AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States (GlobeNewswire) -7.14%
Dec-15-25 08:00AM	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission (GlobeNewswire) +13.31%
Dec-10-25 08:30AM	Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology (GlobeNewswire)
Nov-14-25 09:40AM	Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates (Zacks) +5.22%
08:40AM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-25 05:25PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 08:15AM	Kamada (KMDA) Misses Q3 Earnings Estimates (Zacks)
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:30AM	Loading…
Nov-05-25 08:30AM	Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 (GlobeNewswire)
Nov-04-25 05:15PM	Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-30-25 08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-24-25 08:30AM	Journey Medical Corporation Reports Combined Emrosi (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-21-25 08:30AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout (GlobeNewswire)
Oct-08-25 08:30AM	Journey Medical Corporation to Participate in October 2025 Investor Conferences (GlobeNewswire)
Oct-01-25 08:05AM	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing (GlobeNewswire) -30.72%
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 (GlobeNewswire)
Sep-03-25 08:30AM	Journey Medical Corporation to Participate in September 2025 Investor Conferences (GlobeNewswire)
Sep-02-25 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +15.50%
Aug-18-25 08:30AM	Journey Medical Corporation to Present at the Emerging Growth Conference (GlobeNewswire) +6.13%
Aug-14-25 05:55PM	Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.16%
04:49PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-25 04:01PM	Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-25 08:10AM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 (GlobeNewswire)
Aug-05-25 04:01PM	Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)
Jan-27-25 08:30AM	Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT (GlobeNewswire)
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Jan-07-25 06:59AM	FDA accepts Sentynls Menkes disease therapy NDA for priority review (Pharmaceutical Technology)
Jan-06-25 08:00AM	Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease (PR Newswire)
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease (GlobeNewswire)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Nov-14-24 05:04PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance) -8.92%

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Executive ChairmanDr. Lindsay Allan Rosenwald M.D.

CFO & Head of Corporate DevelopmentMr. David Jin

Chief Strategy OfficerDr. Xiaoqin Lu M.D.

J.D.Mr. Michael S. Weiss Esq.

General Counsel & Corporate SecretaryMr. Samuel Berry

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	May 29 '25	Sale	1.29	100,000	129,000	6,122,249	Jun 03 06:34 PM

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your Finviz experience